Under a tenth of people who could benefit from weight-loss injections including Wegovy are able to get them, caution the global health agency as it issues its first recommendations on the medications.
With in excess of 1,000,000,000 people worldwide now classified as obese, it is urging more widespread and fairer availability to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"The new guidance affirms that excess weight is a long-term condition that can be treated with holistic and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are major barriers to broad availability to the treatments that can help people shift considerable body mass, says the organization.
Weight-Loss Drug Scarcity
Even in the present most optimistic case, the supply of GLP-1 therapies might only reach about 100 million people – under 10% of eligible patients, per the health organization.
The guideline calls on governments and firms to widen availability, through strategies like patent sharing.
The intellectual property rights on semaglutide – the primary ingredient of a leading brand – is scheduled to end in several nations in 2026.
How Obesity Drugs Work
The injections mimick a natural hormone to reduce digestion speed, suppress the appetite and increase the sense of being full so individuals reduce food intake.
People usually start to lose weight in the initial weeks of beginning the once-weekly jabs.
Research indicates users may regain a significant portion a year later of stopping the medication, as their typical food cravings come back.
Being carrying excess weight raises your risk for contracting diseases, like diabetes, heart disease, stroke, and certain cancers.
Excess weight impacts individuals in every country and was linked to millions of deaths worldwide in 2024, according to the health agency.
